New Cooperation｜Chongqing University Cancer Hospital signed a strategic cooperation agreement with Singapore Biotech Company CytoMed Therapeutics

On May 28, 2024, Chongqing University Cancer Hospital and Singapore Biotech Company CytoMed Therapeutics officially signed a strategic cooperation agreement. The signing of this agreement has injected new vitality into the business development of the two sides, which not only helps to realize the sharing of resources and complementary advantages, but also helps to promote the in-depth cooperation between the two sides in technology research and development, personnel training and other aspects.

Through in-depth communication and exchanges in the early stage, the two sides plan to integrate superior resources and have more full and substantive cooperation in laboratory public platform sharing and cooperation, international multi-center clinical trials and other aspects. At the same time, the two sides will also strengthen personnel training and communication, and jointly train high-quality talents with international vision and innovative spirit, so as to provide strong support for the development of both sides.

It is reported that CytoMed Therapeutics was founded in 2018, headquartered in Singapore, the United States Nasdaq high-tech listed company, Biotech Technologies, formerly A spin-off of the Agency for Science, Technology and Research (A * STAR), Singapore's leading government public sector research and development agency, is a deep partner of the National Cancer Centre Singapore, focused on leveraging licensed proprietary technologies to create new stem cell-based immunotherapies for the treatment of human cancer.